Briacell Therapeutics Corp (BCTX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Briacell Therapeutics Corp (BCTX) is down 54.0% since the beginning of the year. At $3 per share, BCTX is trading 90.9% below its 52-week high of $36. Investors who bought $1,000 worth of BCTX shares 5 years ago would now be looking at an investment worth $4.

Briacell Therapeutics Corp (BCTX) has returned -54.01% so far this year and -90.41% over the past 12 months.

Based on dividend-adjusted daily data since Feb 24, 2021, BCTX's average daily return is -0.13%, while the average monthly return is -3.92%.

Historically, 37% of months were positive and 63% were negative. The best month was Jan 2023 with a return of +71.2%, while the worst month was Jul 2025 at -74.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, BCTX closed higher 47% of trading days. The best single day was Jun 2, 2021 with a return of +94.3%, while the worst single day was Jul 15, 2025 at -61.8%.

Briacell Therapeutics Corp has an annualized alpha of -37.60%, beta of 1.07, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 25, 2021.

• This stock participated in 200.73% of S&P 500 Index downside but only -92.75% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BCTX ranks 9 for risk / return — in the bottom 9% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Briacell Therapeutics Corp (BCTX) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Briacell Therapeutics Corp. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Briacell Therapeutics Corp was 99.83%, occurring on May 15, 2026. The portfolio has not yet recovered.

The current Briacell Therapeutics Corp drawdown is 99.82%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Briacell Therapeutics Corp over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Briacell Therapeutics Corp is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.